The Pro Medicus Ltd (ASX: PME) share price is in focus today after the company announced a significant seven-year, A$90 million contract with Boston-based Beth Israel Lahey Health to deliver its full stack imaging platform via the cloud.
What did Pro Medicus report?
- Signed a 7-year, A$90 million contract with Beth Israel Lahey Health
- Full stack contract includes Visage 7 Viewer, Workflow, and Open Archive
- Platform to be delivered via cloud-based implementation
- Contract uses a transaction-based licensing model, offering potential upside
- Go-live rollout targeted for Q1 2027
What else do investors need to know?
Pro Medicus continues to grow its presence in North America, with Beth Israel Lahey Healthâcovering 14 hospitals and over 39,000 staffâjoining an expanding list of clients. The contract covers the migration of existing imaging archives and integration with electronic health records, showing demand for Pro Medicus’ cloud solutions.
The company highlighted its proven cloud-based rollout process, which will commence immediately. This aligns with their broader CloudPACS strategy, aimed at setting industry standards in healthcare imaging IT.
What’s next for Pro Medicus?
The company is focused on the immediate planning and subsequent rollout of its Visage 7 cloud platform at Beth Israel Lahey Health, aiming for a Q1 2027 go-live. Pro Medicus also noted a strong pipeline, with ongoing growth across all market segments and increasing demand for its full suite of imaging products.
Looking longer term, management sees a clear trend toward health providers adopting comprehensive, cloud-based imaging solutions, positioning Pro Medicus for future opportunities.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 56%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
The post Pro Medicus inks $90m contract appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Brambles revises FY26 outlook, announces new US$400m buy-back
- Elders posts higher HY26 profit and holds interim dividend
- Life360 launches US$225m share repurchase to offset dilution
- ALS reports record FY26 earnings and dividend uplift
- What on earth’s going on with Xero shares?
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.